Melatonin Receptor 1B Antibody - BSA Free

Western Blot: Melatonin Receptor 1B AntibodyBSA Free [NLS932]

Western Blot: Melatonin Receptor 1B Antibody [NLS932] - Analysis of 1) HepG2 and 2) A431.

Immunohistochemistry-Paraffin: Melatonin Receptor 1B Antibody - BSA Free [NLS932]

Immunohistochemistry-Paraffin: Melatonin Receptor 1B Antibody [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. Short-term control (C1). Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic Conditions. J Diabetes Res (2015)

Immunohistochemistry-Paraffin: Melatonin Receptor 1B Antibody - BSA Free [NLS932]

Immunohistochemistry-Paraffin: Melatonin Receptor 1B Antibody [NLS932] - Analysis of Human Brain. 8 ug/ ml.

Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932]

Immunohistochemistry: Melatonin Receptor 1B Antibody [NLS932] - Analysis of Human Brain using Fast Red with hematoxylin counterstain.

Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932]

Immunohistochemistry: Melatonin Receptor 1B Antibody [NLS932] - Staining of Mouse Brain.

Immunohistochemistry-Paraffin: Melatonin Receptor 1B Antibody - BSA Free [NLS932]

Immunohistochemistry-Paraffin: Melatonin Receptor 1B Antibody [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. Short-term control treated with MLT (M1). Influence of Melatonin on the Proliferative and Apoptotic Responses of the Prostate under Normal and Hyperglycemic Conditions. J Diabetes Res (2015)

Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] -

Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. (a) Short-term control (C1); (b) short-term control treated with MLT (M1); (c) short-term untreated diabetic (D1); (d) short-term diabetic treated with MLT (MD1); (e) long-term control (C2); (f) long-term control treated with MLT (M2); (g) long-term untreated diabetic (D2); (h) long-term diabetic treated with MLT (MD2). (i) Negative control; (j) positive control, brain tissue section of rat. (k) Relative frequency (%) for MTR1B-positive areas. e: epithelium; l: lumen; s: stroma. Magnification: 400x, bar = 25 μm. Light bars: short-term experiment & dark bars: long-term experiment (N = 5 animals/group). Different lowercase letters indicate significant differences between experimental groups C1, M1, D1, & MD1 (nonparametric data), & different capital letters indicate significant differences between groups C2, M2, D2, & MD2 (parametric data), according to ANOVA followed by the Tukey (post hoc) or Kruskal-Wallis test followed by Dunn's test (post hoc). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26295055), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] -

Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. (a) Short-term control (C1); (b) short-term control treated with MLT (M1); (c) short-term untreated diabetic (D1); (d) short-term diabetic treated with MLT (MD1); (e) long-term control (C2); (f) long-term control treated with MLT (M2); (g) long-term untreated diabetic (D2); (h) long-term diabetic treated with MLT (MD2). (i) Negative control; (j) positive control, brain tissue section of rat. (k) Relative frequency (%) for MTR1B-positive areas. e: epithelium; l: lumen; s: stroma. Magnification: 400x, bar = 25 μm. Light bars: short-term experiment & dark bars: long-term experiment (N = 5 animals/group). Different lowercase letters indicate significant differences between experimental groups C1, M1, D1, & MD1 (nonparametric data), & different capital letters indicate significant differences between groups C2, M2, D2, & MD2 (parametric data), according to ANOVA followed by the Tukey (post hoc) or Kruskal-Wallis test followed by Dunn's test (post hoc). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26295055), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] -

Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. (a) Short-term control (C1); (b) short-term control treated with MLT (M1); (c) short-term untreated diabetic (D1); (d) short-term diabetic treated with MLT (MD1); (e) long-term control (C2); (f) long-term control treated with MLT (M2); (g) long-term untreated diabetic (D2); (h) long-term diabetic treated with MLT (MD2). (i) Negative control; (j) positive control, brain tissue section of rat. (k) Relative frequency (%) for MTR1B-positive areas. e: epithelium; l: lumen; s: stroma. Magnification: 400x, bar = 25 μm. Light bars: short-term experiment & dark bars: long-term experiment (N = 5 animals/group). Different lowercase letters indicate significant differences between experimental groups C1, M1, D1, & MD1 (nonparametric data), & different capital letters indicate significant differences between groups C2, M2, D2, & MD2 (parametric data), according to ANOVA followed by the Tukey (post hoc) or Kruskal-Wallis test followed by Dunn's test (post hoc). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26295055), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Melatonin Receptor 1B Antibody - BSA Free [NLS932] -

Western Blot: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Effects of luzindole on inhibitory action of melatonin on TGF-beta 1-stimulated proliferation & activation in renal interstitial fibroblasts. (A) Reverse transcription-polymerase chain reaction analysis of melatonin receptor type 1A (MT1) & type 1B (MT2) in NRK-49F cells. (B) NRK-49F cells were treated with with TGF-beta 1 (5 ng/mL) after preincubation with vehicle (Veh) or melatonin (Mel; 1mM) in the presence or absence of luzindole (Luz; 100 μM) for 30 min. Cell viability was assessed using CCK-8 assay at 0, 24, & 48 h. The OD was measured at 450 nm. (C) Western blot analysis for alpha-SMA & p-Smad2/3. Cells were treated with TGF-beta 1 (5 ng/mL) for 24 h after preincubation with Veh or Mel (1 mM) in the presence or absence of luzindole (Luz; 20 μM or 100 μM) for 30 min. The graphs show the results of quantitative analysis of alpha-SMA (D) & p-Smad2/3 (E). ** p < 0.01 & *** p < 0.001 vs. Veh-treated cells. #p < 0.05 vs. TGF-beta 1-treated cells. NS: not significant. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31906396), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] -

Immunohistochemistry: Melatonin Receptor 1B Antibody - BSA Free [NLS932] - Tissue localization of melatonin receptor type 1B (MTR1B) in the ventral prostate of rats. (a) Short-term control (C1); (b) short-term control treated with MLT (M1); (c) short-term untreated diabetic (D1); (d) short-term diabetic treated with MLT (MD1); (e) long-term control (C2); (f) long-term control treated with MLT (M2); (g) long-term untreated diabetic (D2); (h) long-term diabetic treated with MLT (MD2). (i) Negative control; (j) positive control, brain tissue section of rat. (k) Relative frequency (%) for MTR1B-positive areas. e: epithelium; l: lumen; s: stroma. Magnification: 400x, bar = 25 μm. Light bars: short-term experiment & dark bars: long-term experiment (N = 5 animals/group). Different lowercase letters indicate significant differences between experimental groups C1, M1, D1, & MD1 (nonparametric data), & different capital letters indicate significant differences between groups C2, M2, D2, & MD2 (parametric data), according to ANOVA followed by the Tukey (post hoc) or Kruskal-Wallis test followed by Dunn's test (post hoc). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26295055), licensed under a CC-BY license. Not internally tested by Novus Biologicals.